Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.12.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DN.1.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.51NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XRNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.350.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.86NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.154NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.4.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.2.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.41NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.137NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.446NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.76 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.398NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.163NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.3 (Theta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.254NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.39.1.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.418NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.9.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.122NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XAJNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.431NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.168NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Q.6 (Alpha)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
AZ.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.97NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.32NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.59NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.67NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.277NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-4348.25US
AY.28 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.272NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.371NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
AA.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.1.353NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.407NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AA.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.160.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.47NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.182NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.218NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.12.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.22 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BM.1.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used